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First, the-placement of intracoronary stents is undoubtedly associated with a reduced rate of restenosis, both angiographic and clinical. Debate exists as to the magnitude of this effect and its possible relation to the diameter of the coronary artery stented, the length of lesion attempted, the morphology of the lesion, the clinical situation in which it is placed, and the design of the stent itself. However, these questions are not fundamental enough to deter the interventionalist from using the device widely.
Second It is for these reasons that BCIS needs to have a very high profile, not only among its members (which includes nearly all interventionalists in the UK) but also with the various professional bodies, particularly the British Cardiac Society, the Royal Colleges and the Department of Health, to try to ensure that appropriate and sensible developments of service occur. Inequality and inequity have been widespread phenomena in the UK health care system, and this has been carefully and systematically documented by the recent CSAG report. This is borne out by recent BCIS audit of interventional procedures in the UK, showing that although the average rate of stent implantation in the country as a whole is approximately 30%, there is a range of 3-75% (BCIS audit returns 1996; unpublished data). The magnitude of this variation is simply too large and there is going to have to be a concerted effort both on the part of interventionalists, and purchasers and provider managers to resolve some of these issues.
Despite these reservations there is no doubt that coronary stenting is a success story, and I think it is remarkable the extent to which it has already gained a foothold given the difficulties and constraints in the UK. There will always be an urgent need for rigorously carried out clinical trials and hopefully the current trials Permins comparing PTCA and stenting with bypass surgery will ultimately prove helpful in clinical decision making. However, one should not forget that, particularly when considering the difficult issue of whether to select a patient for intervention or surgery, surgery itself is going to go through a rapid evolution in the coming years in relation to more minimally invasive techniques. By the time we finally get a good answer as to whether PTCA with stenting is completely equivalent to coronary bypass grafting, the whole stage may have moved in that arena as well.
It is clear that interventional cardiology is going to grow at at least the current rate for some years to come. This is not withstanding the possible explosion that may occur in this specialty if direct intervention for myocardial infarction starts to become established in the UK in the way that it is being established in Europe and North America.
BCIS will continue its commitment to rigorous training and audit of intervention practice in the UK, and there is no doubt that for a while at least the stent will reign supreme within the coronary artery.
1 Black N, Langhan S, Coshall C, Parker J. Impact of the 1991 NHS reforms on the availability and use of coronary revascularisation in the UK (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) large side-branches and in the left main stem. Longer stents allow a range of lengths to be covered. Greater awareness of the role of antiplatelet agents, including IIb/IIIa receptor inhibitors, has reduced the risk of subacute stent occlusion and haemorrhage. Lesions in vessels where the approach to the site of the stenosis is extremely tortuous continue to present a challenging problem but improvements in delivery system design and the use of stiffer wires to straighten the target vessel temporarily make these lesions more amenable, and the contraindication is now relative rather than absolute.
I define only two categories as absolutely unsuitable for stenting. First, lesions that cannot be predilated, identified by persistent indentation during predilatation at whatever pressure is applied. These lesions, if stented, continue to show indentation of the stent, which can be confirmed using intracoronary ultrasound, and the risk of subacute occlusion is high. It is important to distinguish these lesions from those in which the balloon indentation disappears during predilatation but angiography immediately afterwards shows the stenosis to remain because of recoil. These lesions will respond well to stenting. Second, lesions in vessels smaller than 2-5 mm diameter are not stented because of the incidence of thrombosis and restenosis.
